Novartis Venture Fund Foster innovation, drive significant patient benefit and generate superior returns by creating and investing in innovative life science companies

NVF is stage agnostic, engaging in investments from seed- to later-stage life sciences companies across Biotechnology/Biopharma

NVF manages over USD 750 million in committed capital and more than 40 portfolio companies across North America, Europe and Israel

Our primary focus is on the development of novel therapeutics and platforms In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program

We invest in North America, Europe and Israel with approximately USD 750 million under management in committed capital We continue our strategy of making larger focused investments and anticipate total investments up to USD 30 million per company over its life

Invest Across Healthcare Sector:

We make equity investments in Biotechnology/Biopharma life sciences companies NVF is stage agnostic and engages in seed investments as well as later-stage investments We typically lead or co-lead an investment and play an active role on company boards

Total number of jobs created

1000 Total dollars under management approximately $750 million 18 Phase 1 and 2 clinical programs Dr Laura Brass is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA Prior to joining NVF, Laura was a Managing Director at MPM Capital, and prior to that, she was a member of the founding management team and SVP of Business Development for TriNetX, a healthcare IT company focusing on big data analytics for clinical research Before TriNetX, Laura was Director of Business Development at Harvard University's Office of Technology Development and at its Wyss Institute for Biologically Inspired Engineering She led commercialization strategy, start-up creation, deal structuring, and negotiations for a portfolio of over 250 biotech, synthetic chemistry, engineering, software, device, and stem cell technologies developed at Harvard and Harvard-affiliated institutions Laura has also held roles in business development and IP strategy at Elixir Pharmaceuticals, and was CEO of Aferon, Inc , an early-stage antiviral start-up company Laura holds a B A in Philosophy and a B S in Biochemistry from the University of Missouri-Columbia, and a Ph D in Molecular Genetics and Cell Biology and an M B A from the University of Chicago

Anokion (Board Seat) Expansion (Observer) Faze Medicines (Board Seat) Immunitas Therapeutics (Board Seat) Ribon Therapeutics (Board Seat) Bart Dzikowski is a Managing Director at the Novartis Venture Fund and its Head of Transactions & Legal based in Basel, Switzerland Prior to joining NVF, Bart held various senior roles in Novartis' Corporate Legal M&A and Business Development & Licensing groups Before joining Novartis in 2009, Bart was a Vice President with the Investment Banking Division of Bank of America/Merrill Lynch in New York and, before that, he was an attorney with the Corporate/M&A Group at the law firm of Allen & Overy LLP in New York Bart holds a Juris Doctor (J D ) and Civil Law (B C L ) degrees from McGill Law School in Canada and is a member of the New York State Bar

Enterprise Therapeutics (Board Seat) Oculis (Board Seat) UZH Life Sciences Fund (Board Seat) Enterprise TMEM16A (Acquired by Roche) Inflazome (Acquired by Roche) Dr Anja König is the Global Head of the Novartis Venture Fund in Basel, Switzerland Previously, she was a Managing Director at NVF investing in Switzerland, U K and the rest of Europe as well as Asia/Pacific Prior to joining NVF, she was an Associate Partner at McKinsey and Company in New York, where she worked with healthcare companies in the US, Europe and Emerging Markets Anja holds a PhD in physics from Cornell University She is active in the Swiss startup ecosystem and is a member of Stiftungsrat and Stiftungsratsausschuss of the Swiss National Science Foundation

Arctos Medical AG (Acquired by Novartis) Bicycle Therapeutics (IPO) Covagen AG (Acquired by J&J) Forendo Pharma (M&A) Genedata (Buy Back) Heptares Therapeutics, Ltd (Acquired by Sosei) Nabriva Therapeutics (IPO) PharmAbcine (IPO) Qurient Therapeutics (IPO) Arctos Medical AG (Acquired by Novartis) Dr Florian Muellershausen is a Managing Director at the Novartis Venture Fund in Basel, Switzerland Prior to joining Novartis Venture Fund, he worked as a Scientific Manager for the R&D Committee of the Novartis Board of Directors and, before that held various scientific and drug discovery roles at the Novartis Institute of Biomedical Research (NIBR) including as Laboratory Head in target discovery and in early clinical research as Translational Medicine Expert, Autoimmunity Florian received his MSc degree in Biochemistry from Free University Berlin and his PhD degree with great distinction in Biochemistry from Ruhr University Bochum and completed his post-doctoral training at NIBR in Switzerland

Amphista (Board Seat) Anaveon (Board Seat) FoRx Therapeutics (Board Seat) Granite Bio (Board Seat) LoQus23 Therapeutics (Board Seat) SpliceBio (Observer) Dr Aaron Nelson is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA Prior to joining NVF, he was an investor at dRx Capital, the joint investment company of Novartis and Qualcomm, focused on Digital Medicine Previously, Aaron worked on technology strategy across multiple Business Units within Novartis, including Strategic Project Leader for the Trials of The Future program and Group Head in the Investigative Toxicology organization Aaron studied medicine at Tufts University, cell and microbiology at the University of Pennsylvania and the Karolinska Institutet, and completed his undergraduate studies at Cornell University

Exo Therapeutics (Board Seat) ImmPACT-Bio (Observer) TigaTx (Board Seat) Lemonaid Health (Acquired by 23andMe) Dr Nandita Shangari is a Managing Director at the Novartis Venture Fund in Cambridge, MA USA Prior to joining NVF, she was part of the Novartis Oncology Business Development and Licensing team where she managed key alliances for the Oncology Portfolio Before that, Nandita, held the Global Program Team Director position as part of the Kymriah® Global Program Team and helped bring this novel cell therapy to market, for two indications, in the US and EU Nandita has also held strategic and group head roles in the Novartis Preclinical Investigative Toxicology organization Nandita received her B Sc in Biochemistry and Ph D in Pharmaceutical Sciences from the University of Toronto, Canada

GentiBio (Observer) Immunitas Therapeutics (Board Seat) Capstan (Board Seat) Tscan (IPO) Renovacor (SPAC) Dr Neeta Shenoy is an Associate at the Novartis Venture Fund in Cambridge, MA, USA Prior to joining NVF, she worked as a Discovery Toxicologist in Takeda’s Drug Safety & Evaluation Group Before Takeda, Neeta was a lab head at the Novartis Institutes of Biomedical Research, where she was in charge of the biomarker consulting group in preclinical safety tasked with developing translational biomarker strategies and was a preclinical safety representative and biomarker expert on cross-functional project teams spanning multiple disease areas Neeta received her MSc in biotechnology from the University of Bombay and her PhD in immunology from Rush University in Chicago She did her postdoctoral research training at the University of Massachusetts in Worcester and Northwestern University in Chicago

Michal Silverberg is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA Prior to joining NVF, she was a Senior Partner at Takeda Ventures and, before that, worked at Novo Nordisk in roles of increasing responsibility including as Senior Director Business Development and New Product Commercialization, serving as a member of the BioPharm leadership team Since 1998, Michal has held positions in various sectors of the life science industry including in the Office of the Chief Scientist of Israel (The Incubator program), venture capital (Ofer Brothers Hi Tech) and global pharmaceutical and biotech companies, including various positions at MGVS, an Israeli biotech company and at OSI Pharmaceuticals in a business development role She received her B A in Economics and Business Management from Haifa University, her M B A from Tel-Aviv University in Israel and her Master's degree in Biotechnology from Columbia University in New York

GentiBio (Board Seat) ForeBio (Board Seat) ImmPACT-Bio (Board Seat) Twentyeight-Seven (Board Seat) Adicet Bio (IPO) Cavion (Acquired by Jazz Pharmaceuticals) Forma Therapeutics (IPO) Viamet Therapeutics (Acquired by NovaQuest Capital Management) Prof Patrick Aebischer is President emeritus of the École Polytechnique Fédérale de Lausanne (EPFL) and a member of its Brain Mind Institute Patrick Aebischer trained as an MD (1980) and a Neuroscientist (1983) at the Universities of Geneva and Fribourg in Switzerland Prior to joining EPFL, he held Faculty positions at Brown University and the University of Lausanne He has received numerous honors, including the Robert Bing Prize of the Swiss Academy of Medicine and the Pfizer Foundation Prize for Clinical Neurosciences He serves as a Senate Member of the "Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) He is a member of the scientific committee of the Italian Institute of Technology and a member of the Singapore Biomedical Sciences International Advisory Council Prof Aebischer is a member of the Board of Lonza, Nestlé and Logitech and a founder of three biotech companies He is a senior partner of NanoDimension-III

Professor School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL); former Director of the Swiss Institute for Experimental Cancer Research (ISREC); Director of the National Center of Competence in Research (NCCR) in Molecular Oncology

Harry Kirsch is the Chief Financial Officer of Novartis and a member of the Executive Committee of Novartis Prior to his current position, he served as CFO of the company's Pharmaceuticals Division Under his leadership, the division's core operating income margin increased, in constant currencies, every quarter of 2011 and 2012 despite patent expirations Harry joined Novartis in 2003 from Procter & Gamble in the United States, where he was a CFO of P&G's global pharmaceutical business and held various finance positions at divisional, regional, country and manufacturing site level, as well as in P&G Global Business Services organization Harry also represents Novartis on the board of the GSK Consumer Healthcare joint venture Harry holds a degree in industrial engineering and economics from the University of Karlsruhe in Germany

Nobel Prize Winner for Chemistry, Coll�ge de France, Paris, Universit� Louis Pasteur, Strasbourg, France

Director of Research, Institut Curie, Paris, France

Dr Christoph A Meier is the Head of the Department of Internal Medicine at the University Hospital Zurich, and Professor at the Medical Faculty of the University of Geneva Prior to his current role, he was the Chief Medical Officer and deputy CEO at the University Hospital Basel and, before that, the Chief of the Department of Internal Medicine & Specialties and a member of the Board of Directors at Triemli Hospital in Zurich, Switzerland, as well as Chief of Endocrinology and Head of the Laboratory of Molecular Endocrinology at the University Hospital Geneva Dr Meier received his Medical Degree from the University of Basel in Switzerland and holds his Swiss Board Certification (FMH) in Internal Medicine and Endocrinology & Diabetology Dr Meier completed his medical residency at the University Hospital of Geneva and was a a Postdoctoral Fellow at the National Institutes of Health in the Molecular, Cellular Nutritional Endocrinology Branch in Bethesda, MD (USA) He was also a Howard Hughes Medical Institute Physician Fellow at the Division of Genetics, Brigham and Women's Hospital, as well as a Clinical Fellow in Endocrinology, Diabetes and Metabolism at the Massachusetts General Hospital, Harvard Medical School